Natera Inc (NTRA) - News Archive

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity In a significant advancement in the field of precision medicine, Natera, Inc. (NASDAQ...

In a groundbreaking development for bladder cancer treatment, Natera, Inc. (NASDAQ: NTRA), a pioneer in cell-free DNA and precision medicine, has announced compelling results from the randomized, double-blind, phase 3 I...

Natera Inc. (NASDAQ: NTRA), a leading entity in the realm of cell-free DNA and precision medicine, has announced a significant progression in its clinical research with the activation of the NRG Oncology trial, ARCHER (...

In the fast-paced world of genetic testing, Natera, Inc. (NASDAQ: NTRA) has taken significant steps to solidify its position as a leader in the field. The Austin-based company recently announced the issuance of a new pa...

In a groundbreaking announcement from Austin, Texas, Natera, Inc. (NASDAQ: NTRA), a leading figure in the realm of cell-free DNA and genetic testing, has unveiled remarkable findings from its pioneering DEFINE-HT study...

Natera s Groundbreaking Study on Heart Transplant Recipients and Improved Financial Resilience In a groundbreaking move for the field of transplantation medicine, Natera, Inc. (NASDAQ: NTRA) has been selected to present...

NCCN Strengthens Guidance on ctDNA in Colon, Rectal, and Merkel Cell Carcinoma: Pioneering Advances by Natera In an evolving landscape of cancer diagnostics and treatment, Natera, Inc. (NASDAQ: NTRA), a trailblazer in c...

Natera Announces National Commercial Coverage for Its Fetal RhD NIPT In an exciting development for expectant parents and healthcare providers, Natera, Inc. (NASDAQ: NTRA), a pioneering force in cell-free DNA (cfDNA) an...

Natera Unveils Pioneering Results from Landmark Phase III Clinical Trial for Colorectal Cancer In a groundbreaking presentation at the 2025 American Society of Clinical Oncology s Gastrointestinal Cancers Symposium in S...

Natera to Present Groundbreaking Data at the 2025 ASCO GI Symposium in San Francisco AUSTIN, Texas Natera, Inc. (NASDAQ: NTRA), a pioneer in the field of cell-free DNA and genetic testing, is poised to make significant...

Natera and MyOme Introduce Integrated Polygenic Risk Score for Breast Cancer, While Financial Stability Reflects Industry LeadershipIn a significant advancement for personalized medicine, Natera, Inc. (NASDAQ: NTRA), a...

Natera, Inc. (NASDAQ: NTRA), a global frontrunner in cell-free DNA and genetic diagnostics, recently cemented its position at the vanguard of prenatal testing with the publication of its latest clinical validation study...

Natera Inc. a leading entity in the realm of cell-free DNA and genetic testing, has achieved another significant breakthrough as its Prospera Lung test has obtained Medicare coverage under the Centers for Medicare & Med...

A Breath of Fresh Air: Medicare Coverage for Natera s Prospera Lung Test Targets Single Lung Transplants In a significant stride for post-transplant care, Natera, Inc. a pioneer in cell-free DNA and genetic testing anno...

Natera, Inc. (NASDAQ: NTRA), a front-runner in the field of cell-free DNA and genetic testing, has recently garnered significant recognition. The company’s co-founder and executive chairman, Matthew Rabinowitz, PhD, was...

Decoding the Future: Natera s Signatera™ Surges Forward with 100 Peer-Reviewed Milestones In the world of genetics, where every discovery illuminates pathways previously shrouded in mystery, Natera, Inc. stands brillian...

At the recent European Society for Medical Oncology (ESMO) Congress in Barcelona, Natera, Inc. (NASDAQ: NTRA), unveiled promising results from its GALAXY study, a key segment of the ambitious CIRCULATE-Japan trial. This...

Natera to Present Groundbreaking Signatera Colorectal Cancer Data at ESMO 2024 By Author Name Austin, Texas - Natera, Inc. (NASDAQ: NTRA), a renowned global leader in cell-free DNA and genetic testing, has announced its...

for CSIMarket.com : Natera s Signatera Validated for Clinical Utility in Merkel Cell Carcinoma Amid Launch of New Cancer Trial Austin, Texas - Natera Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing...

In the rapidly evolving landscape of oncology, Natera, Inc. (NASDAQ: NTRA) continues to establish itself as a formidable leader in cell-free DNA (cfDNA) and genetic testing. The company s recent developments highlightin...